Theseus Pharmaceuticals, Inc. (THRX): Price and Financial Metrics


Theseus Pharmaceuticals, Inc. (THRX): $12.13

0.33 (+2.80%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add THRX to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

THRX Stock Price Chart Interactive Chart >

Price chart for THRX

THRX Price/Volume Stats

Current price $12.13 52-week high $15.21
Prev. close $11.80 52-week low $4.01
Day low $11.60 Volume 95,543
Day high $12.54 Avg. volume 556,883
50-day MA $7.29 Dividend yield N/A
200-day MA $7.07 Market Cap 469.59M

Theseus Pharmaceuticals, Inc. (THRX) Company Bio


Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-variant inhibitor for activating and resistance mutations of the KIT kinase or a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors (GIST), a type of cancer characterized by oncogenic activation of KIT. The company also develops fourth-generation EGFR inhibitor that is active against C797S, an EGFR mutation that causes resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.


THRX Latest News Stream


Event/Time News Detail
Loading, please wait...

THRX Latest Social Stream


Loading social stream, please wait...

View Full THRX Social Stream

Latest THRX News From Around the Web

Below are the latest news stories about THESEUS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate THRX as an investment opportunity.

NMTR and SLRX among healthcare movers

Gainers: NovoCure NVCR +51%.Zai Lab ZLAB +42%.Theseus Pharmaceuticals (THRX) +12%.Salarius Pharmaceuticals (SLRX) +14%.9 Meters Biopharma (NMTR) +14%.Losers: Nuwellis…

Seeking Alpha | January 5, 2023

Theseus Pharmaceuticals Highlights Key Anticipated 2023 Milestones and Announces BCR-ABL as Target for Third Development Program

Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development, and commercialization of transformative targeted therapies, today announced key anticipated milestones for 2023 and introduced its third development program, a pan-variant tyrosine kinase inhibitor (TKI) targeting BCR-ABL for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosom

Yahoo | January 5, 2023

Theseus Pharmaceuticals Inc. (THRX) Is A Buy Stock For Small Caps – Analysts

Theseus Pharmaceuticals Inc. (NASDAQ:THRX) has seen 0.51 million shares traded in the recent trading session. The company, currently valued at $204.96M, closed the recent trade at $6.04 per share which meant it gained $0.83 on the day or 15.93% during that session. The THRX stock price is -151.82% off its 52-week high price of $15.21 … Theseus Pharmaceuticals Inc. (THRX) Is A Buy Stock For Small Caps – Analysts Read More »

Marketing Sentinel | January 4, 2023

Have you been able to find a good deal on Theseus Pharmaceuticals Inc.’s shares?

Theseus Pharmaceuticals Inc. (NASDAQ:THRX) marked $5.06 per share on Thursday, up from a previous closing price of $4.96. While Theseus Pharmaceuticals Inc. has overperformed by 2.02%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, THRX fell by -54.37%, with highs and lows ranging from $15.21 to […]

US Post News | December 30, 2022

Investing in These 2 Biotech Stocks Could Double Your Money, Says Analyst

Let’s talk about biotech. These stocks present a unique set of attractions for investors, especially investors willing to shoulder some extra risk. To start with, biotech firms have a famously high overhead, and equally long lead-times for product development. But that is balanced by the opportunity for huge gains – sales profits, and share appreciation – when a new drug shows strongly positive clinical trial results, or receives regulatory approval for commercialization. To give an example, jus

Yahoo | December 15, 2022

Read More 'THRX' Stories Here

THRX Price Returns

1-mo 144.56%
3-mo 120.55%
6-mo 68.24%
1-year 38.63%
3-year N/A
5-year N/A
YTD 143.57%
2022 -60.73%
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6426 seconds.